These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

92 related articles for article (PubMed ID: 25894261)

  • 1. [Treatment of GLP1 receptor agonists and body mass control].
    Žák P; Olšovský J
    Vnitr Lek; 2015 Apr; 61(4):316-9. PubMed ID: 25894261
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Beyond glycemic control in type 2 diabetes. Promises and gambles of therapy with glucagon-like peptide-1 receptor agonists].
    Mannucci E
    G Ital Cardiol (Rome); 2011 Dec; 12(12 Suppl 2):3-4. PubMed ID: 22158420
    [No Abstract]   [Full Text] [Related]  

  • 3. [Possibilities of therapy GLP1 RA for diabetics with nephropathy].
    Adamíková A
    Vnitr Lek; 2015 Apr; 61(4):312-5. PubMed ID: 25894260
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Glucagon-like peptide-1 receptors agonists (GLP1 RA).
    Kalra S
    J Pak Med Assoc; 2013 Oct; 63(10):1312-5. PubMed ID: 24392570
    [TBL] [Abstract][Full Text] [Related]  

  • 5. GLP-1 receptor agonists for type 2 diabetes mellitus: recent developments and emerging agents.
    Trujillo JM; Nuffer W
    Pharmacotherapy; 2014 Nov; 34(11):1174-86. PubMed ID: 25382096
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Glucagon-like peptide-1 receptor agonists in type 2 diabetes: a meta-analysis of randomized clinical trials.
    Monami M; Marchionni N; Mannucci E
    Eur J Endocrinol; 2009 Jun; 160(6):909-17. PubMed ID: 19318378
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Glucagon-like peptide-1 agonists.
    Padwal R
    BMJ; 2012 Jan; 344():d7282. PubMed ID: 22236410
    [No Abstract]   [Full Text] [Related]  

  • 8. [GLP-1 receptor agonists versus SGLT-2 inhibitors in obese type 2 diabetes patients].
    Marques AR; Jaafar J; de Kalbermatten B; Philippe J
    Rev Med Suisse; 2015 Jun; 11(477):1227-8, 1230-3. PubMed ID: 26211282
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Beyond glucose lowering: glucagon-like peptide-1 receptor agonists, body weight and the cardiovascular system.
    Vergès B; Bonnard C; Renard E
    Diabetes Metab; 2011 Dec; 37(6):477-88. PubMed ID: 21871831
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment of type 2 diabetes with glucagon-like peptide-1 receptor agonists.
    Hansen KB; Knop FK; Holst JJ; Vilsbøll T
    Int J Clin Pract; 2009 Aug; 63(8):1154-60. PubMed ID: 19624785
    [TBL] [Abstract][Full Text] [Related]  

  • 11. GLP-1 Receptor Agonist Treatment Increases Bone Formation and Prevents Bone Loss in Weight-Reduced Obese Women.
    Iepsen EW; Lundgren JR; Hartmann B; Pedersen O; Hansen T; Jørgensen NR; Jensen JE; Holst JJ; Madsbad S; Torekov SS
    J Clin Endocrinol Metab; 2015 Aug; 100(8):2909-17. PubMed ID: 26043228
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Therapies for inter-relating diabetes and obesity - GLP-1 and obesity.
    Iepsen EW; Torekov SS; Holst JJ
    Expert Opin Pharmacother; 2014 Dec; 15(17):2487-500. PubMed ID: 25260877
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes.
    Drucker DJ; Nauck MA
    Lancet; 2006 Nov; 368(9548):1696-705. PubMed ID: 17098089
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Glycaemic efficacy of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors as add-on therapy to metformin in subjects with type 2 diabetes-a review and meta analysis.
    Deacon CF; Mannucci E; Ahrén B
    Diabetes Obes Metab; 2012 Aug; 14(8):762-7. PubMed ID: 22471248
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Liraglutide therapy in obese people with type 2 diabetes - experience of a weight management centre.
    Elkhenini H; New JP; Summers LK; Syed AA
    Eur J Intern Med; 2014 Mar; 25(3):e38-9. PubMed ID: 24412647
    [No Abstract]   [Full Text] [Related]  

  • 16. GLP-1R agonists are not a quick fix for weight loss.
    Iverson KA
    BMJ; 2012 Feb; 344():e1455; author reply e1459. PubMed ID: 22374905
    [No Abstract]   [Full Text] [Related]  

  • 17. Utility of GLP-1R agonists in diabetes requires long term study.
    de Oliveira JM
    BMJ; 2012 Feb; 344():e1451; author reply e1459. PubMed ID: 22374904
    [No Abstract]   [Full Text] [Related]  

  • 18. The pharmacologic basis for clinical differences among GLP-1 receptor agonists and DPP-4 inhibitors.
    Morales J
    Postgrad Med; 2011 Nov; 123(6):189-201. PubMed ID: 22104467
    [TBL] [Abstract][Full Text] [Related]  

  • 19. GLP-1 receptor agonists today.
    Marre M; Penfornis A
    Diabetes Res Clin Pract; 2011 Sep; 93(3):317-27. PubMed ID: 21767888
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Glucagon-like peptide-1 receptor agonists vs. insulin in inadequately controlled patients with type 2 diabetes. Is this meta-analysis miscalculated?
    Liatis S; Makrilakis K
    Diabetes Obes Metab; 2014 Mar; 16(3):284. PubMed ID: 24495116
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.